Your Child's genes: a new clue in fighting a rare cancer?
NCT ID NCT02902874
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This study looks at whether natural variations in immune-related genes affect how well children with a rare type of lymphoma (ALCL) respond to treatment. By analyzing blood samples from 185 patients, researchers hope to find genetic markers linked to longer periods without the disease progressing. The goal is to better understand why some children respond better than others and potentially guide more personalized treatment in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Blood sample analysis
- What this could lead to
- If certain gene variations are linked to better outcomes, this could help personalize treatment for children with ALCL.
- What could go wrong
- This is an observational study, so it cannot prove cause and effect. The findings may not lead to immediate changes in treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gustave Roussy
Villejuif, Val de Marne, 94805, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart immune cell with a kill switch beat tough lymphomas?
- New hope for rare lymphoma: lorlatinib trial targets Drug-Resistant cancers
- Massive T-Cell lymphoma database aims to unlock new insights
- New drug combo targets Hard-to-Treat lymphomas
- New hope for blood cancer patients in japan?
- New hope for kids with rare cancers: brigatinib trial opens